Lipid lowering with PCSK9 inhibitors

RT Dadu, CM Ballantyne - Nature Reviews Cardiology, 2014 - nature.com
Statins are the most-effective therapy currently available for lowering the LDL-cholesterol
(LDL-C) level and preventing cardiovascular events. Additional therapies are necessary for …

Clinical aspects of PCSK9

B Cariou, C Le May, P Costet - Atherosclerosis, 2011 - Elsevier
Proprotein convertase subtilisin kexin type 9 (PCSK9) is a circulating protein that impairs
LDL clearance by promoting the LDL receptor (LDLR) degradation. PCSK9 has emerged as …

Dynamic incorporation of multiple in silico functional annotations empowers rare variant association analysis of large whole-genome sequencing studies at scale

X Li, Z Li, H Zhou, SM Gaynor, Y Liu, H Chen, R Sun… - Nature …, 2020 - nature.com
Large-scale whole-genome sequencing studies have enabled the analysis of rare variants
(RVs) associated with complex phenotypes. Commonly used RV association tests have …

[HTML][HTML] National Lipid Association recommendations for patient-centered management of dyslipidemia: part 2

TA Jacobson, KC Maki, CE Orringer, PH Jones… - Journal of clinical …, 2015 - Elsevier
Abstract An Expert Panel convened by the National Lipid Association previously developed
a consensus set of recommendations for the patient-centered management of dyslipidemia …

PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future

YJ Shimada, CP Cannon - European heart journal, 2015 - academic.oup.com
Reduction in low-density lipoprotein cholesterol (LDL-C), mainly with statins, has decreased
the risk of cardiovascular events over the last few decades. However, there are several …

Genome-wide characterization of shared and distinct genetic components that influence blood lipid levels in ethnically diverse human populations

MA Coram, Q Duan, TJ Hoffmann, T Thornton… - The American Journal of …, 2013 - cell.com
Blood lipid concentrations are heritable risk factors associated with atherosclerosis and
cardiovascular diseases. Lipid traits exhibit considerable variation among populations of …

PCSK9 Loss-of-Function Variants, Low-Density Lipoprotein Cholesterol, and Risk of Coronary Heart Disease and Stroke: Data From 9 Studies of Blacks and Whites

ST Kent, RS Rosenson, CL Avery… - Circulation …, 2017 - Am Heart Assoc
Background—PCSK9 loss-of-function (LOF) variants allow for the examination of the effects
of lifetime reduced low-density lipoprotein cholesterol (LDL-C) on cardiovascular events. We …

Living the PCSK9 Adventure: from the Identification of a New Gene in Familial Hypercholesterolemia Towards a Potential New Class of Anticholesterol Drugs

M Abifadel, S Elbitar, P El Khoury, Y Ghaleb… - Current atherosclerosis …, 2014 - Springer
A decade after our discovery of the involvement of proprotein convertase subtilisin/kexin
type 9 (PCSK9) in cholesterol metabolism through the identification of the first mutations …

[HTML][HTML] An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes

L Zhang, T McCabe, JH Condra, YG Ni… - … journal of biological …, 2012 - ncbi.nlm.nih.gov
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a promising therapeutic target for
treating coronary heart disease. We report a novel antibody 1B20 that binds to PCSK9 with …

Association of proprotein convertase subtilisin/kexin type 9 (PCSK9) with cardiovascular risk in primary prevention

YM Zhu, TJ Anderson, K Sikdar, M Fung… - … , and vascular biology, 2015 - Am Heart Assoc
Objective—Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays an important role in
the modulation of low-density lipoprotein metabolism. This study was conducted to evaluate …